Comparison of the efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine for late-staged gastric cancer in aged patients
10.3760/cma.j.issn.1008-6315.2009.07.007
- VernacularTitle:多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较
- Author:
Xiaobing CHEN
;
Suxia LUO
;
Xiaohui GAO
;
Lili HAN
;
Ning LI
;
Wenying DENG
;
Mengqiang ZHOU
;
Zhenhe SUO
- Publication Type:Journal Article
- Keywords:
Docetaxe;
Oxaliplatin;
Capecitabine;
elderly;
Advanced gastric cancer
- From:
Clinical Medicine of China
2009;25(7):689-691
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.
